← Leaderboards
Peter W Hunt
University Of California San Francisco
$24,497,989
Attributed
$36,751,758
Total exposure
20
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,751,758 · 20
By mechanism
R01$28,122,259 · 9
P30$2,169,325 · 2
RM1$1,969,877 · 1
R56$1,803,059 · 3
R21$1,049,530 · 3
K24$921,450 · 1
Top collaborators
- Laurence Huang9 shared
- Suneil Krishna Koliwad9 shared
- Jue Lin8 shared
- Barbara L Shacklett8 shared
- Priscilla Y. Hsue6 shared
- Ahmed A Tawakol6 shared
- Steven A Yukl2 shared
- Bradley E Aouizerat1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Matthew Lawrence Springer$13,274,009
- Reese T. Jones$7,250,168
- Stanton Arnold Glantz$34,445,026
- Joel Palefsky$28,104,336
- Thomas J. Coates$58,121,154
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortHiv InfectionsAntiretroviral TherapyMediatingPathway InteractionsCytomegalovirusImmune ActivationInflammationCellsViralCo-InfectionAgingBiological MarkersT-LymphocytePersonsParticipantPharmaceutical PreparationsMortalityChronicGeneral PopulationMorbidity - Disease RateInflammatoryPathogenesisAcquired Immunodeficiency Syndrome
Grant awards (66)
Impact of Asymptomatic CMV on Cardiovascular Event Risk in Treated HIV$2,981,544
R01 · FY2025 · HL · contact PI
Stimulant and Polysubstance use, Inflammation and Sex Effects on Myocardial Disease in HIV (SPISE)$1,969,877
RM1 · FY2025 · DA
Understanding and targeting the HIV-expressing reservoir to reduce immune activation$795,083
R01 · FY2025 · AI
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIV$775,096
R01 · FY2025 · DK
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$759,975
R01 · FY2025 · AI
Basic and Translational Science Core$449,477
P30 · FY2025 · AI · contact PI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$64,687
R01 · FY2025 · AI
Understanding and targeting the HIV-expressing reservoir to reduce immune activation$834,937
R01 · FY2024 · AI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$767,807
R01 · FY2024 · AI
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$751,857
R01 · FY2024 · HL
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIV$700,000
R01 · FY2024 · DK
Basic and Translational Science Core$511,569
P30 · FY2024 · AI · contact PI
Persistent Functional Immune Defects in Treated HIV Infection$184,290
K24 · FY2024 · AI · contact PI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$90,056
R01 · FY2024 · AI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$770,507
R01 · FY2023 · AI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$765,877
R01 · FY2023 · HL · contact PI
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$750,252
R01 · FY2023 · HL
Basic and Translational Science Core$581,117
P30 · FY2023 · AI · contact PI
Persistent Functional Immune Defects in Treated HIV Infection$184,290
K24 · FY2023 · AI · contact PI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$93,412
R01 · FY2023 · HL · contact PI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$87,416
R01 · FY2023 · AI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$78,069
R01 · FY2023 · HL · contact PI
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$53,069
R01 · FY2023 · HL
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$764,059
R01 · FY2022 · AI
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$750,787
R01 · FY2022 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$726,136
R01 · FY2022 · HL · contact PI
Basic and Translational Science Core$627,162
P30 · FY2022 · AI · contact PI
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIV$564,215
R56 · FY2022 · DK
Persistent Functional Immune Defects in Treated HIV Infection$184,290
K24 · FY2022 · AI · contact PI
Inflammation, Aging, Microbes, Obstructive Lung Disease, and Diffusion Abnormalities (I AM OLD-DA): Pulmonary function in females, evaluating the menopausal transition and immune activation (pFEMI).$159,182
R01 · FY2022 · HL
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$91,667
R01 · FY2022 · HL
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study - Diversity Supplement$38,599
R01 · FY2022 · HL
Plasma Proteomic and Metabolomic Predictors of Vascular Disease in Treated HIV$788,897
R56 · FY2021 · HL · contact PI
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV$772,678
R01 · FY2021 · AI
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$749,503
R01 · FY2021 · HL
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$726,542
R01 · FY2021 · DK
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$668,476
R01 · FY2021 · HL · contact PI
Persistent Functional Immune Defects in Treated HIV Infection$184,290
K24 · FY2021 · AI · contact PI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$869,817
R01 · FY2020 · DK
Inflammation, Aging, Microbes, Obstructive Lung Disease and Diffusion Abnormalities (I AM OLD-DA) Study$755,040
R01 · FY2020 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$675,844
R01 · FY2020 · HL · contact PI
Persistent Functional Immune Defects in Treated HIV Infection$184,290
K24 · FY2020 · AI · contact PI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$768,378
R01 · FY2019 · DK
Timing of ART and homeostasis of the persistent HIV reservoir in the adult$702,186
R01 · FY2019 · AI · contact PI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$116,302
R01 · FY2019 · DK
Determinants of Functional Immune Defects in Treated HIV Infection and Aging$783,355
R01 · FY2018 · AI · contact PI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$780,389
R01 · FY2018 · DK
Timing of ART and homeostasis of the persistent HIV reservoir in the adult$716,396
R01 · FY2018 · AI · contact PI
Immunologic and Fat-Associated Predictors of Insulin Resistance in Treated HIV$792,500
R01 · FY2017 · DK
Determinants of Functional Immune Defects in Treated HIV Infection and Aging$786,968
R01 · FY2017 · AI · contact PI
Timing of ART and homeostasis of the persistent HIV reservoir in the adult$725,934
R01 · FY2017 · AI · contact PI
Determinants of Functional Immune Defects in Treated HIV Infection and Aging$751,471
R01 · FY2016 · AI · contact PI
Timing of ART and homeostasis of the persistent HIV reservoir in the adult$740,979
R01 · FY2016 · AI · contact PI
The impact of TB co-infection on the reservoir of persistent HIV in vivo$196,815
R21 · FY2016 · AI · contact PI
Determinants of Functional Immune Defects in Treated HIV Infection and Aging$799,919
R01 · FY2015 · AI · contact PI
Determinants of Functional Immune Defects in Treated HIV Infection and Aging$789,508
R01 · FY2014 · AI · contact PI
IDO-induced Tryptophan Catabolism and Mortality in Treated HIV-infected Africans$449,947
R56 · FY2012 · AI · contact PI
Inflammation, T Cell Senescence, and Mortality in Treated HIV Infection$192,049
R21 · FY2011 · AI · contact PI
Inflammation, T Cell Senescence, and Mortality in Treated HIV Infection$246,239
R21 · FY2010 · AI · contact PI
Innate Immune Response Genetics and T cell Activation in Treated HIV Infection$187,901
R21 · FY2010 · AI · contact PI
Innate Immune Response Genetics and T cell Activation in Treated HIV Infection$226,526
R21 · FY2009 · AI · contact PI
The Determinants of T Cell Activation in HIV Infection$148,722
K23 · FY2009 · AI · contact PI
The Determinants of T Cell Activation in HIV Infection$148,722
K23 · FY2008 · AI · contact PI
The Determinants of T Cell Activation in HIV Infection$148,714
K23 · FY2007 · AI · contact PI
The Determinants of T Cell Activation in HIV Infection$148,770
K23 · FY2006 · AI · contact PI
The Determinants of T Cell Activation in HIV Infection$121,330
K23 · FY2005 · AI